Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 19/20 | 0.64 |
| ▸ | CA1 | P00915 | 17/20 | 0.64 |
| ▸ | CA9 | Q16790 | 16/20 | 0.64 |
| ▸ | CA12 | O43570 | 14/20 | 0.64 |
| ▸ | CA5A | P35218 | 9/20 | 0.59 |
| ▸ | CA7 | P43166 | 9/20 | 0.59 |
| ▸ | CA5B | Q9Y2D0 | 9/20 | 0.59 |
| ▸ | CA6 | P23280 | 7/20 | 0.59 |
| ▸ | CA4 | P22748 | 7/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.59 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.59 |
| ▸ | CA3 | P07451 | 3/20 | 0.56 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3534525 | 0.97 | CA2 (0.62) | CA2CA1CA9CA12CA5A | |
| Iodide SCHEMBL28552080 | 0.97 | CA2 (0.62) | CA2CA1CA9CA12CA5A | |
| SCHEMBL202948 | 0.85 | CA2 (0.81) | CA2CA1CA9CA12CA5A | |
| Benzenesulfonamide SCHEMBL5671646 | 0.82 | CA2 (0.76) | CA2CA1CA9CA12CA5A | |
| SCHEMBL673381 | 0.80 | CA12 (1.00) | CA2CA1CA9CA12CA7 | |
| SCHEMBL8973815 | 0.80 | CA2 (0.52) | CA2CA1CA9CA12CA5A | |
| Sulfanilamide SCHEMBL27605551 | 0.80 | CA2 (0.68) | CA2CA1CA9CA12CA5A | |
| SCHEMBL3404140 | 0.79 | CA1 (0.73) | CA2CA1CA9CA12CA4 | |
| SCHEMBL22029377 | 0.78 | CA12 (0.71) | CA2CA1CA9CA12CA5A | |
| SCHEMBL10493509 | 0.77 | CA2 (0.68) | CA2CA1CA9CA12CA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024115549-A1 | ARYL- AND HETEROARYL-SULFONAMIDE DERIVATIVES AS CCR8 MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-06 | — | — | WO | claimed |
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-11-12 | — | — | US | claimed |
| CN-102558056-B | Celecoxib and preparing method thereof | JIANGSU FANGSHENG PHARMACEUTICAL CO LTD | 2014-04-09 | — | — | CN | claimed |
| CN-102558056-A | Celecoxib and preparing method thereof | HUNAN FANGSHENG PHARMACEUTICAL CO LTD | 2012-07-11 | — | — | CN | claimed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | claimed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | claimed |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | ILLIG CARL R (US) | 2001-10-18 | — | — | US | claimed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | claimed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | claimed |
| EP-0757674-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE $g(b) 3? AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | Merck & Co., Inc. (US) | 1997-02-12 | — | — | EP | claimed |
| WO-1995029159-A1 | SUBSTITUTED SULFONAMIDES AS SELECTIVE β3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY | MERCK & CO., INC. (US) | 1995-11-02 | — | — | WO | claimed |
| WO-2026104679-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104681-A1 | NEW SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026104680-A1 | NOVEL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-4457871-A | Preparation of trans cyclohexane,1,4-diisocyanate and related compounds | AKZONA INCORPORATED (US) | 1984-07-03 | — | — | US | disclosed |
| US-4439370-A | Preparation of trans cyclohexane 1,4-diisocyanate | AKZONA INCORPORATED (US) | 1984-03-27 | — | — | US | disclosed |
| US-4418211-A | Preparation of trans-cyclohexane-1,4-disulphonyl urea | AKZONA INCORPORATED (US) | 1983-11-29 | — | — | US | disclosed |
| US-4275223-A | Preparation of trans-cyclohexane-1,4-diurethanes | AKZONA INCORPORATED (US) | 1981-06-23 | — | — | US | disclosed |
| US-4203916-A | Preparation of trans cyclohexane 1,4 diisocyanate | AKZONA INCORPORATED (US) | 1980-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322094-A1 | USE OF SUBSTITUTED 2,3-DIHYDRO-1-BENZOFURAN-4-CARBOXYLIC ACIDS OR SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | CAT, HSF1, HPD | CA2 341/4885CA1 1091/4885CA9 1495/4885 |
| US-20010031781-A1 | Heteroaryl amidines, methylamidines and guanidines and use thereof as protease inhibitors | SERPINE1, PRSS3, PRSS2 | CA2 2597/4885CA1 2080/4885CA9 1517/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | CA2 3086/4885CA1 3778/4885CA9 1910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.